Comparision between effective doses of Brolucizumab in Diabetic Macular Edema
Not Applicable
- Registration Number
- CTRI/2023/06/054105
- Lead Sponsor
- Army hospital research and referal delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age more than 18 years with type 1 or type 2 diabetes.
centre involving diabetic macular edema.
Exclusion Criteria
1. Media opacity interfering with OCT acquistion
2. Prior treatement with laser photocoagulation
3.Prior Anti VEGF or Steroid administration
4. Decreased visual acuity due to causes other than diabetic macular edema
5.Macular edema due to unknown causes
6. Uncontrolled DM, HTN, Pregnancy, Lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The changes in central macular thickness, after intravitreal brolucizumab 6.0mg (group-1) vs 3.6mg (group-2) at 0wk to 24 wkTimepoint: The changes in central macular thickness, after intravitreal brolucizumab 6.0mg (group-1) vs 3.6mg (group-2) at 0wk to 24 wk
- Secondary Outcome Measures
Name Time Method To compare the changes in best corrected visual acuity in treatment of naive centre involving diabetic macular edema after intravitreal BROLUCIZUMAB 6.0mg vs 3.6mgTimepoint: To compare the changes in best corrected visual acuity in treatment of naive centre involving diabetic macular edema after intravitreal BROLUCIZUMAB 6.0mg vs 3.6mg